Manual therapy for ankle pain in hemophilia patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the safety and effectiveness of a manual therapy protocol for patients suffering from hemophilic ankle arthropathy. The study involves a randomized crossover design with 13 participants who will receive either the manual therapy or a placebo over a period of three weeks. Each therapy session lasts 50 minutes and aims to relieve pain, improve mobility, and enhance overall joint function. Participants will be assessed at the beginning, after the intervention, and during a follow-up period to measure outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients diagnosed with haemophilia A and B
* With severe haemophilia phenotype (\<1% FVIII/FIX)
* Over 18 years of age
* With a medical diagnosis of ankle arthropathy and with clinical assessment using the Hemophilia Joint Health Score
* On prophylactic or on-demand treatment with coagulation factor VIII/FIX concentrates

Exclusion Criteria:

* Patients with neurological or cognitive disorders that prevent them from understanding the questionnaires and physical tests
* Failure to sign the informed consent document

Where it's running

• Universidad Católica San Antonio
  Murcia, Spain Recruiting

Study contacts

• Principal investigator: Rubén Cuesta-Barriuso, PhD — Universidad de Oviedo
• Study coordinator: Rubén Cuesta-Barriuso, PhD
• Email: cuestaruben@uniovi.es
• Phone: 607547274

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• First‑in‑human test of ARD001 in healthy adults and people with hemophilia A

  This study tests ARD001 to see if it is safe and tolerable in healthy adults and in people with hemophilia A, using a single dose (Phase 1) and potentially repeated doses (Phase 2) if results look good.

  Recruiting Phase 1/2 Arditus Pte Ltd · Singapore · NCT07787091

• Hemophilia A: comparing long-acting FVIII replacement vs non-FVIII therapy in kids

  This study tests whether children with moderate to severe Hemophilia A on long-acting FVIII or non-FVIII therapies form clots differently and develop small joint bleeds or early joint changes.

  Recruiting University of Texas Southwestern Medical Center · Dallas, Texas · NCT07692217

• SR604: a new treatment tested in adults with Hemophilia A/B or congenital Factor VII deficiency

  This study tests a single and multiple doses of SR604 to see if it is safe and effective for adults with Hemophilia A or B, with or without inhibitors, and for those with congenital Factor VII deficiency.

  Recruiting at 7 sites Phase 1/2 Shanghai RAAS Blood Products Co., Ltd. · Changsha and 8 other locations · NCT07644832

• Bone health in severe hemophilia A: emicizumab vs efanesoctocog alfa

  This study tests whether bone density and bone health markers differ in adults with severe hemophilia A who use emicizumab versus efanesoctocog alfa for prophylaxis.

  Recruiting Arkansas Children's Hospital Research Institute · Little Rock, Arkansas · NCT07582276

• Joint health, balance, and quality of life in adults with hemophilia A

  See how joint damage and postural balance relate to quality of life in adults with severe hemophilia A.

  Recruiting Yuzuncu Yil University · Van · NCT07523399

• NXT007 versus emicizumab to prevent bleeds in people with Hemophilia A

  This will test whether NXT007 prevents bleeding better than emicizumab in people aged 12 and older with Hemophilia A, including those with or without factor VIII inhibitors.

  Recruiting at 63 sites Phase 3 Hoffmann-La Roche · Orange, California and 62 other locations · NCT07416604

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.